Interest in GENTING 3182 GENTING BERHAD spurred by progress in Alzheimer's treatment
KUALA LUMPUR: At 9.43am, Genting Bhd's stock was down eight sen or 1.53% to RM5.16 a share, trimming the previous session's steep gains that were underpinned by TauRx Pharmaceuticals Ltd's progress in the development of a drug for Alzheimer's disease.
Genting had seen a surge in investor interest as 20.3%-owned TauRx, a global leader in tau-based research, released optimistic data from the Phase 3 clinical trial of an oral drug for Alzheimer's disease called HMTM.
The FBM KLCI blue-chip ended Wednesday's session 49 sen or 10.3% higher at a seven-month high of RM5.24 on the back of 89.15 million units traded
"The output indicates that participants receiving HMTM decline at a rate substantially less than is typical in Alzheimer's based on published research.
"This was seen for both cognitive and functional endpoints across a broad range of severity from mild cognitive impairment (MCI) to moderate Alzheimer's. Importantly, the safety profile is favourable and consistent with previous studies," said TauRX executive chairman and co-founder Professor Claude Wischik in announcing its clinical trial findings on Wednesday.
"Our data analysis is ongoing and will be reported at a later date. We look forward to providing an update on our progress on 9th June 2022 at the 35th Global Conference of Alzheimer's Disease International," he added.
Offering its take on the development, RHB Research said TauRx's press release did not represent positive top-line results for the trial, dubbed LUCIDITY, but expects it to put HMTM in a favourable spot to receive the necessary regulatory approvals.
According to TauRx's COO, if the trial shows positive top-line results, it could pave the way to accelerated regulatory review and approvals, and the subsequent market launch of the drug, which could be by late-2023.
"We are positive on this development as it marks a step forward for TauRx to potentially bring HMTM to the market, providing greater visibility to its path to profitability," said RHB.
The research firm said it believes the Street, like itself, has yet to factor TauRx into Genting's valuations, which offers upside to the consensus target price.
It cited a March 2018 news report that TauRx claimed a US$2.5bil valuation, while the company COO said in May 2021 that it had secured an investment of about US$700mil to fund its research.
"Assuming a valuation range of US$700mil-2.5bil, Genting’s 20.3% stake could be worth 16-58 sen per share, representing a 3-9% enhancement to our current target price," said RHB.
However, the research firm said it chose not to include TauRx in Genting's sum-of-parts valuation for now, pending greater clarity on its valuations.
It maintained its "buy" call on the stock with a target price of RM6.37, which offers 22% upside to the closing price on Wednesday.
https://www.thestar.com.my/business/business-news/2022/06/02/interest-in-genting-spurred-by-progress-in-alzhemier039s-treatment
Singapore Investment
-
-
-
No surprise that AI’s bagging the bucks3 hours ago
-
-
I Bought MPACT4 hours ago
-
-
-
-
Brutal bruising of some Stock Indices11 hours ago
-
Portfolio Update12 hours ago
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Beware Of Scams1 day ago
-
-
-
Buying a home for face2 days ago
-
-
-
-
-
-
-
-
-
-
-
-
Finance Investment Movement 445 days ago
-
-
-
-
Going REITs Shopping Again6 days ago
-
-
Weekly Markets Outlook6 days ago
-
Market indeed coming down6 days ago
-
Cory Diary : Dividend Q1 '246 days ago
-
-
-
-
-
-
-
-
Banks and Miles Report – Mar 20241 week ago
-
-
Revisiting Bitcoin1 week ago
-
-
-
-
-
-
2024 (Portfolio Update)2 weeks ago
-
-
-
-
Retirement Journey Update for March 20242 weeks ago
-
-
-
1Q 2024 Investment Strategy Update2 weeks ago
-
-
Portfolio Summary for March 20242 weeks ago
-
Reasonable Dividend Yield 2024Q23 weeks ago
-
-
-
Portfolio (March 30, 2024)3 weeks ago
-
-
-
QAF #77 - 2023 Annual Report3 weeks ago
-
Lentor Hills Residences3 weeks ago
-
Burnt out!3 weeks ago
-
-
-
Feb 2024 Expenditure3 weeks ago
-
-
Starting Our Second Property Cycle4 weeks ago
-
-
-
-
-
-
-
-
-
Feb 2024 Portfolio1 month ago
-
-
Summary of February 20241 month ago
-
The Market Is A Scam!1 month ago
-
-
-
-
-
-
-
-
Options Trading Journal Jan 20242 months ago
-
-
-
-
-
-
-
-
End of 2023 Review3 months ago
-
-
Year 2023 DIYQuant Portfolio Performance Report3 months ago
-
Monthly Summary of November 20234 months ago
-
3 Simple Poker Strategies for Beginners4 months ago
-
Migration of website4 months ago
-
-
Abandon REITS?4 months ago
-
-
-
-
-
-
-
-
-
August 2023 Portfolio Updates7 months ago
-
-
-
-
Hello SP Group, I'm Back!9 months ago
-
-
-
-
A New Light11 months ago
-
-
-
-
-
-
-
Demoralized1 year ago
-
2022 Thoughts, Hello 2023!1 year ago
-
Series of Defaults for Maple Finance1 year ago
-
Takeaways from “Sea Change”1 year ago
-
-
Greed is Coming Back1 year ago
-
-
-
-
-
-
-
-
-
-
-
What is Overemployment1 year ago
-
-
-
-
-
-
-
-
-
-
-